Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Progestogens in prostatic cancer.

L Denis, G Declercq

    European Urology
    |January 1, 1978
    PubMed
    Summary
    This summary is machine-generated.

    High doses of 6alpha-methyl-17alpha-hydroxyprogesterone acetate (MAP) showed no response in relapsed prostate cancer patients. However, untreated patients demonstrated objective or subjective responses to MAP treatment.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Real life data of ONC201 (dordaviprone) in pediatric and adult H3K27-altered recurrent diffuse midline glioma: Results of an international academia-driven compassionate use program.

    European journal of cancer (Oxford, England : 1990)·2024
    Same author

    Investigation of the parameters used in fused deposition modeling of poly(lactic acid) to optimize 3D printing sessions.

    International journal of pharmaceutics·2019
    Same author

    Reframing schizophrenia and autism as bodily self-consciousness disorders leading to a deficit of theory of mind and empathy with social communication impairments.

    Neuroscience and biobehavioral reviews·2019
    Same author

    The oral Janus kinase/spleen tyrosine kinase inhibitor ASN002 demonstrates efficacy and improves associated systemic inflammation in patients with moderate-to-severe atopic dermatitis: results from a randomized double-blind placebo-controlled study.

    The British journal of dermatology·2019
    Same author

    Reverse shoulder arthroplasty in young patient with achondroplasia - Ten year follow up: Case report.

    Orthopaedics & traumatology, surgery & research : OTSR·2017
    Same author

    Cost-effectiveness of prostate cancer screening: a simulation study based on ERSPC data.

    Journal of the National Cancer Institute·2014
    Same journal

    Re: McKay RR, Pal S, Xie W, et al. Advanced Urologic Cancer Consensus Conference (AUC3) 2025: Expert Consensus on the Management of Renal Cell and Urinary Tract Cancers. CA Cancer J Clin 2026;76:e70052.

    European urology·2026
    Same journal

    Re: Ultra-hypofractionated Stereotactic Ablative Body Radiotherapy for Primary Renal Cell Carcinoma: 5-year Outcomes from a Pooled Analysis of the FASTRACK Trials.

    European urology·2026
    Same journal

    Re: Alexander D. Sherry, Van To, Criselle D'souza, et al. Metastasis-directed Therapy With or Without Pembrolizumab for Oligometastatic Clear Cell Renal Cell Carcinoma: Pooled Analysis of Two Prospective Single-arm Phase 2 Trials. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2026.03.024.

    European urology·2026
    Same journal

    Re: Hormone Therapy Use and Duration with Postoperative Radiotherapy for Recurrent Prostate Cancer: an Individual Patient Data Meta-analysis.

    European urology·2026
    Same journal

    Re: Nguyen DD, Tadayon Najafabadi B, Lin L, et al. Effect of Prostate Cancer Screening with Prostate-specific Antigen Testing on Long-term Prostate Cancer-specific Mortality: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2026.04.005.

    European urology·2026
    Same journal

    Histological Subtypes and Divergent Differentiation of Urothelial Carcinoma: Histology, Genomics, and Management Implications.

    European urology·2026
    See all related articles

    Area of Science:

    • Oncology
    • Endocrinology

    Background:

    • Prostate cancer remains a significant health concern.
    • Hormonal therapies are a cornerstone in managing advanced prostate cancer.

    Purpose of the Study:

    • To evaluate the efficacy of high-dose 6alpha-methyl-17alpha-hydroxyprogesterone acetate (MAP) in patients with prostate cancer.
    • To assess MAP's effectiveness in both relapsed and untreated prostate cancer cases.

    Main Methods:

    • A cohort of 20 patients with histologically confirmed prostate cancer was treated.
    • High doses of MAP were administered to all participants.
    • Patient responses were categorized as objective and/or subjective.

    Main Results:

    • No response to MAP was observed in 9 patients with relapsed prostate cancer.

    Related Experiment Videos

  • 6 out of 11 untreated patients exhibited an objective and/or subjective response to MAP.
  • This suggests a differential efficacy of MAP based on disease status.

    • Conclusions:

    • High-dose MAP may not be effective for prostate cancer in relapse.
    • MAP demonstrates potential therapeutic value in untreated prostate cancer patients.
    • Further research is warranted to elucidate MAP's role in prostate cancer management.